Related Experiment Video

Updated: Jun 26, 2025

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma
06:08

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma

Published on: June 2, 2023

1.7K

Ponatinib-review of historical development, current status, and future research

Hagop M Kantarjian1, Helen T Chifotides1, Fadi G Haddad1

  • 1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

American Journal of Hematology
|May 10, 2024
PubMed

Insights

Ponatinib, a potent third-generation tyrosine kinase inhibitor (TKI), effectively treats Philadelphia chromosome-positive leukemias, including resistant mutations. Response-based dosing enhances tolerance and reduces toxicity in chronic myeloid leukemia (CML).

Area of Science:

  • Hematology
  • Oncology
  • Pharmacology

Background:

  • Philadelphia chromosome-positive (Ph+) leukemias, such as chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL), are driven by BCR::ABL1 fusion genes.
  • Resistance to first- and second-generation tyrosine kinase inhibitors (TKIs) remains a significant clinical challenge, particularly mutations like T315I.
  • Third-generation TKIs offer new therapeutic options for patients with resistant or intolerant Ph+ leukemias.

Purpose of the Study:

  • To review the efficacy and safety of ponatinib, a third-generation BCR::ABL1 TKI.
  • To highlight ponatinib's role in treating T315I-mutated Ph+ leukemias and other resistant CML and Ph+ ALL cases.
  • To discuss the impact of response-based dosing and future directions for ponatinib in leukemia treatment.

Main Methods:

  • Literature review of clinical trials and studies on ponatinib.
  • Analysis of ponatinib's efficacy in various BCR::ABL1-positive leukemia settings.
  • Evaluation of safety profiles and toxicity management, including response-based dosing strategies.

Main Results:

  • Ponatinib demonstrates high potency against Ph+ leukemias, including T315I-mutated CML and Ph+ ALL.
  • Response-based dosing in chronic phase CML (CP-CML) improved treatment tolerance and reduced cardiovascular risks.
  • Ponatinib-based therapy shows superior outcomes in frontline Ph+ ALL, establishing it as a new standard of care.

Conclusions:

  • Ponatinib is a crucial therapeutic option for patients with T315I-mutated CML and Ph+ ALL, and for those resistant to prior TKIs.
  • Optimized dosing strategies, such as response-based dosing, enhance ponatinib's tolerability and safety.
  • Continued development of third-generation TKIs and combination therapies promises further advancements in treating Ph+ leukemias.

More Related Videos

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-308:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

1.1K
Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors08:45

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Published on: July 17, 2020

6.2K

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
157
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K
Preclinical Development: Overview01:28

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.4K
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.9K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
Drug Discovery: Overview01:26

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
7.8K